Xencor (XNCR)
(Delayed Data from NSDQ)
$21.29 USD
+0.86 (4.21%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.27 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.29 USD
+0.86 (4.21%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.27 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
by Zacks Equity Research
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -25.88% and 0.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Xencor (XNCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 59.34% and 119.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 33.33% and 40.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 75.90% and 8.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 69.3% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Xencor (XNCR) points to a 74.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 28.57% and 78.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?